Method of identifying a biologically-active composition from a biofilm

Inventors

Berkes, Eva A. • Monsul, Nicholas T. • BOEHM, Frederick T.

Assignees

Quorum Innovations Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11191277-B2

Patent

Publication Date

2021-12-07

Expiration Date


Abstract

The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.

Core Innovation

The invention relates to compositions and methods for non-antibiotic anti-biofilm and anti-inflammatory therapy using natural, non-toxic ingredients. A key aspect is the use of probiotic organisms, including viable or nonviable probiotic organisms such as Lactobacillus and S. thermophilus, in combination with biofilm-disruptive and anti-microbial components including anti-microbial honey (e.g., manuka honey / Medi-Honey).

The document describes therapeutic concepts directed to pathogenic biofilms and inflammation, including mechanisms such as supporting innate immunity and dispersing or disrupting biofilm via interference with the biofilm EPS matrix and/or quorum sensing. The disclosed compositions can optionally include prebiotics and other natural ingredients, and they are presented as non-antibiotic approaches targeting chronic biofilm-associated conditions.

The disclosure further characterizes biofilm activity using measures such as biofilm inhibitory concentration and minimum biofilm eradication concentration (MBEC), alongside other related assays. It also provides local delivery formulation examples, including inhalant solution using an inhaler device, and indicates use cases such as dry eye and other ocular or adnexal inflammation, as well as additional chronic biofilm-associated conditions including rhinosinusitis, periodontitis, respiratory disorders, and skin disorders.

Claims Coverage

The document portion provided includes one independent claim. That claim introduces two principal inventive aspects: an inhaler device containing a composition with a nonviable biofilm cellular mass of a Lactobacillus microbe, and an associated biological activity limited to anti-microbial activity and/or anti-inflammatory activity.

Inhaler device with nonviable biofilm cellular mass of Lactobacillus

An inhaler device containing a composition comprising biologically-active biofilm cellular mass of a Lactobacillus microbe, wherein the biofilm cellular mass is nonviable.

Anti-microbial and/or anti-inflammatory biological activity of the nonviable biofilm cellular mass

The biological activity of nonviable biofilm cellular mass is anti-microbial activity and/or anti-inflammatory activity.

In the provided independent claim, the inventive scope is defined by combining an inhaler device with a composition containing nonviable Lactobacillus biofilm cellular mass, where the nonviable mass is biologically-active specifically for anti-microbial and/or anti-inflammatory activity.

Stated Advantages

Non-antibiotic anti-biofilm and anti-inflammatory therapy using natural, non-toxic ingredients.

Anti-microbial and/or anti-inflammatory biological activity associated with a nonviable biofilm cellular mass.

Documented Applications

Dry eye and other ocular/adnexal inflammation, including dry eye syndrome and meibomian gland dysfunction.

Chronic biofilm-associated conditions including rhinosinusitis.

Periodontitis.

Respiratory disorders.

Skin disorders.

Use of an inhaler device with an inhalant solution as a local delivery form.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.